|
Disease course and in-hospital treatments
|
|
Mean period from symptom onset to hospital admission (± SD)—days
|
6.4 (± 8.0)
|
6.4 (± 6.2)
|
6.4 (± 9.6)
|
-
|
|
Mean period from symptom onset to COVID-19 diagnosis (± SD)—days
|
7.7 (± 4.2)
|
7.6 (± 4.3)
|
7.7 (± 4)
|
-
|
|
Transfer from inundated area—no. (%)
|
47 (25.0)
|
20 (20.8)
|
27 (29.3)
|
-
|
|
Proven co-infection—no. (%)
|
21 (11.2)
|
11 (11.5)
|
10 (10.9)
|
-
|
|
Initial empirical antibiotic therapy—no. (%)
|
169 (89.9)
|
87 (90.6)
|
82 (89.1)
|
0.71 [0.34–1.48], p = 0.360
|
|
Antiviral therapy—no. (%)
|
112 (59.6)
|
57 (59.4)
|
55 (59.8)
|
0.95 [0.63–1.43], p = 0.790
|
|
Lopinavir/ritonavir—no. (%)
|
64 (34.0)
|
31 (32.3)
|
33 (35.9)
|
1.04 [0.69–1.56], p = 0.860
|
|
Remdesivir—no. (%)
|
10 (5.3)
|
5 (5.2)
|
5 (5.4)
|
1.00 [0.43–2.33], p = 1.000
|
|
Hydroxychloroquine—no. (%)
|
42 (22.3)
|
22 (22.9)
|
20 (21.7)
|
0.94 [0.58–1.52], p = 0.800
|
|
Immunomodulatory drugs—no. (%)
|
22 (11.7)
|
10 (10.4)
|
12 (13)
| |
|
Corticosteroids—no. (%)
|
21 (11.2)
|
10 (10.4)
|
11 (12)
|
1.00 [0.57–1.76], p = 1.000
|
|
Tocilizumab—no. (%)
|
1 (0.5)
|
-
|
1 (1.1)
|
–
|
|
Mean period between hospital admission and intubation (± SD)—days
|
2.6 (± 7.5)
|
2.5 (± 5.3)
|
2.7 (± 9.2)
|
–
|
|
Vasopressor support—no. (%)
|
128 (68.1)
|
57 (59.4)
|
71 (77.2)
|
1.94 [1.22–3.09], p = 0.005
|
|
Average duration of mechanical ventilation (± SD)—days
|
22.2 (± 16.7)
|
14.5 (± 11.3)
|
30.3 (± 17.7)
|
-
|
|
ECMO—no. (%)
|
18 (9.6)
|
4 (4.2)
|
14 (15.2)
|
3.09 [1.59, 6.03], p = 0.001
|
|
Outcome
|
|
Deceased on May 20th—no. (%)
|
54 (28.7)
|
26 (27)
|
28 (30.4)
| |
|
Discharged alive from ICU on May 20th—no. (%)
|
115 (61.2)
|
64 (66.7)
|
51 (55.4)
| |
|
Still in ICU on May 20th—no. (%)
|
19 (10.1)
|
6 (6.3)
|
13 (14.1)
| |
